Institut Carnot OPALE, The Organization for Partnerships in Leukemia, is proud to announce a strategic partnership with the renowned Shanghai Institute of Hematology (SIH) at Ruijin Hospital, China.
This collaboration aims to drive transformative research and development projects to address global medical and industrial unmet needs in leukemias and related diseases, together the deadliest blood cancer.
Why this matters: our partnership builds on a rich legacy of leukemia research collaboration initiated at Institut de Recherche Saint-Louis (IRSL) in the 1980s by Prof. Laurent Degos, Prof. Hugues de Thé and Prof. Zhu Chen, which continued to thrive with contributions from leading experts like Prof. François Sigaux and Prof. Saijuan Chen, and more recently, Prof. Hervé Dombret and Prof. Weili Zhao.
Together, thanks to the expertise of our hundreds of researchers, to our large specialized clinical networks, to our yearly access to thousands of patients, and to our unique platforms and disease models we are committed to pushing the boundaries of leukemia research.
Our objective: this cooperation aligns with OPALE's strategy to build privileged, long-term relationships with a leading hematology institute in China and in the US, respectively.
The goal of the present agreement is to accelerate leukemia therapeutic and diagnostic innovation along the full R&D value chain through joint research projects involving top scientists from SIH and from the OPALE national consortium.
Our scope includes all types of leukemias, myelodysplastic syndromes, myeloproliferative neoplasms and other related disorders.
Concerned therapeutics are targeted therapies, CAR-T cells, chemotherapy, immunotherapy and cell therapy.
We have already identified two promising projects to kickstart this initiative, for which industry partners will be sought.
Mark your calendars: join us at the LEUKEMIA360 international event in Paris on November 13. Among many other topics, we will discuss this strategic cooperation and its impact on our industrial partners interested in the leukemia market.
Companies, save the date!